Loading
Total declarations
Companies
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Latest filing published 23 Feb 2016 for Theravance Biopharma, Inc., €227k.
Insider track record
Disclosed buys
7
Disclosed sells
0
Signal history
No signal scores available.
Closed purchases
Market purchases
7
Positive at T+90
50%
Median T+90
+4.7%
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +71.0%Entry US$10.73 · Close at T+365 US$18.36
- +29.7%Entry US$8.48 · Close at T+365 US$10.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Leonard M. Blum: trading record in brief
Leonard M. Blum discloses dealings in 3 companies, chiefly Innoviva, Inc., Icos Corp and Theravance Biopharma, Inc. In total, 44 filings cover trades dated from 29 December 2005 to 20 February 2016.
Every open-market trade on record is a purchase: 7 purchases worth €464k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 34 share grants.
The median purchase comes to €35k. After 4 purchases with a full 90-day history, the hit rate stands at 50% and the median 90-day move at +4.7%. This is a record of the past, not a forecast.
The latest filing, published on 23 February 2016, reports a share grant of €227k in Theravance Biopharma, Inc. The last insider purchase was made public on 26 February 2010, 6,083 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Leonard M. Blum
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations40 total
16,101 shares@ US$15.65100.0% of flowOrdinary SharesSEC:0001179110-16-019957:0
673 shares@ US$14.24Ordinary SharesSEC:0001179110-15-008526:0
90,000 shares0Ordinary SharesSEC:0001179110-15-002168:0
28,365 shares0Common StockSEC:0001179110-14-010615:0
50,000 shares0Common StockSEC:0001179110-14-009784:0
21,000 shares0Common StockSEC:0001179110-14-009784:1
18,849 shares@ US$26.86Common StockSEC:0001179110-14-008228:0
37,500 shares0Common StockSEC:0001179110-14-007349:0
4,311 shares@ US$39.98Common StockSEC:0001179110-14-003521:0
5,000 shares0Common StockSEC:0001179110-13-012216:0
3,292 shares@ US$37.01Common StockSEC:0001179110-13-008886:0
5,000 shares0Common StockSEC:0001179110-13-002419:0
5,000 shares0Common StockSEC:0001179110-12-015262:0
7,546 shares@ US$29.69CommonStockSEC:0001179110-12-012204:0
5,000 shares0Common StockSEC:0001179110-12-003023:0
12,500 shares0Common StockSEC:0001179110-11-002794:0
100,000 shares0Common StockSEC:0001179110-11-002794:1
12,500 shares0Common StockSEC:0001179110-10-015347:0
1,686 shares@ US$13.02Common StockSEC:0001179110-10-009144:0
12,025 shares@ US$10.48Common StockSEC:0001179110-10-003992:0
Canonical exit: 25 May 2010 (T+90)
677 shares@ US$10.33Common StockSEC:0001179110-10-003992:1
Canonical exit: 26 May 2010 (T+90)
1,335 shares@ US$10.22Common StockSEC:0001179110-10-003534:0
25,000 shares0Common StockSEC:0001179110-10-002754:0
1,114 shares@ US$14.04Common StockSEC:0001179110-09-015916:0
1,084 shares@ US$15.65Common StockSEC:0001179110-09-012457:0
25 of 40 declarations
